Table 4 Results of the Survival Analysis in GIST
From: Cyclin H expression is increased in GIST with very-highrisk of malignancy
Non-Disease-specific | 1-year | 3-year | 5-year | |||
|---|---|---|---|---|---|---|
Overall survival | 91% | 79% | 71% | |||
1-year DSS (%) | 3-year DSS (%) | 5-year DSS (%) | 1-year DFS (%) | 3-year DFS (%) | 5-year DFS (%) | |
Whole cohort | ||||||
Survival | 96 | 87 | 84 | 80 | 76 | 72 |
Risk of malignancy according to Fletcher et al. 2002 [1] | ||||||
Very low | 100 | 100 | 100 | 100 | 100 | 100 |
Low | 100 | 95 | 95 | 95 | 95 | 95 |
Intermediate | 100 | 100 | 100 | 100 | 100 | 100 |
High | 89 | 71 | 65 | 53 | 44 | 38 |
Non-high | 100 | 98 | 98 | 98 | 98 | 98 |
Cyclin H | ||||||
Positive | 90 | 80 | 72 | 78 | 67 | 67 |
Negative | 97 | 89 | 87 | 80 | 79 | 73 |
Other criteria | ||||||
Prim-local | 100 | 97 | 94 | 95 | 90 | 85 |
Prim-metastasis | 72 | 33 | 33 | -- | -- | -- |
Met: any time | 84 | 56 | 46 | 27 | 19 | 8 |
R 0 resection | 97 | 94 | 90 | 88 | 86 | 85 |
R 1/2 resection | 83 | 40 | 40 | 33 | 25 | 25 |